Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress [Yahoo!...
Ocean Biomedical, Inc. (OCEA)
Company Research
Source: Yahoo! Finance
patients following a single, low dose, prime-only intramuscular injection of VRON-0200 VRON-0200 was well tolerated, with no serious adverse events (SAEs), study patient discontinuations, or laboratory abnormalities observed in 870 patient days on treatment VRON-0200 induced CD8+ T cell responses in the majority (5 of 9) of patients Responses were observed even in patients with limited pre-existing immunity A 4-fold increase in T cell responses at Day 28 was observed in the 5 responders At Day 91, several patients maintained T cell responses above their pre-treatment values June 5, 2024 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies , today announced positive immunologic and continued safety and tolerability data, from the first-ever human study of its novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure, presented by Professor Ed Gane , M.D., from the U
Show less
Read more
Impact Snapshot
Event Time:
OCEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCEA alerts
High impacting Ocean Biomedical, Inc. news events
Weekly update
A roundup of the hottest topics
OCEA
News
- Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 [Yahoo! Finance]Yahoo! Finance
- Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024GlobeNewswire
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q [Yahoo! Finance]Yahoo! Finance
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QGlobeNewswire
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease [Yahoo! Finance]Yahoo! Finance
OCEA
Sec Filings
- 5/30/24 - Form 8-K
- 5/14/24 - Form NT
- 4/24/24 - Form 8-K
- OCEA's page on the SEC website